Table 4

Multivariable analysis of factors for OS and PFS in ALKneg ALCL, AITL, TCL U, and EATL patients up to age 70 treated with CHOP/CHOEP

OS (n = 248)PFS (n = 243)
HR (95% CI)PHR (95% CI)P
Age 1.003 (0.984-1.023) .730 1.000 (0.982-1.018) .998 
Male gender 1.60 (1.12-2.29) .010 1.66 (1.16-2.35) .005 
Ann Arbor III-IV 1.56 (1.03-2.31) .028 1.54 (1.05-2.25) .028 
Extranodal involvement >1 1.55 (1.03-2.35) .037 1.57 (1.04-2.35) .030 
WHO PS >0 1.78 (1.23-2.57) .002 1.81 (1.26-2.60) .001 
PTCL NOS 1.00 — 1.00 — 
ALKneg ALCL 0.81 (0.50-1.25) .307 0.78 (0.50-1.21) .261 
AITL 0.90 (0.59-1.39) .643 0.90 (0.59-1.38) .628 
EATL 1.92 (1.18-3.14) .009 1.52 (0.95-2.45) .083 
TCL U 1.98 (0.96-4.09) .066 2.05 (0.99-4.24) .052 
Etoposide 0.81 (0.53-1.25) .341 0.87 (0.57-1.32) .507 
Auto-SCT ITT 0.58 (0.40-0.84) .004 0.56 (0.39-0.81) .002 
OS (n = 248)PFS (n = 243)
HR (95% CI)PHR (95% CI)P
Age 1.003 (0.984-1.023) .730 1.000 (0.982-1.018) .998 
Male gender 1.60 (1.12-2.29) .010 1.66 (1.16-2.35) .005 
Ann Arbor III-IV 1.56 (1.03-2.31) .028 1.54 (1.05-2.25) .028 
Extranodal involvement >1 1.55 (1.03-2.35) .037 1.57 (1.04-2.35) .030 
WHO PS >0 1.78 (1.23-2.57) .002 1.81 (1.26-2.60) .001 
PTCL NOS 1.00 — 1.00 — 
ALKneg ALCL 0.81 (0.50-1.25) .307 0.78 (0.50-1.21) .261 
AITL 0.90 (0.59-1.39) .643 0.90 (0.59-1.38) .628 
EATL 1.92 (1.18-3.14) .009 1.52 (0.95-2.45) .083 
TCL U 1.98 (0.96-4.09) .066 2.05 (0.99-4.24) .052 
Etoposide 0.81 (0.53-1.25) .341 0.87 (0.57-1.32) .507 
Auto-SCT ITT 0.58 (0.40-0.84) .004 0.56 (0.39-0.81) .002 

Auto-SCT ITT, patients planned for high-dose chemotherapy and autologous stem cell transplantation; etoposide, addition of etoposide to CHOP.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal